ReviewBiotechnology for biofuels and bioproducts2025
Current trends in the production of xylitol and paving the way for metabolic engineering in microbes.
Review in Biotechnology for biofuels and bioproducts, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- A Review on Xylooligosaccharides Production From Lignocellulosic Biomass: Strategies, Applications, and Challenges.ChemSusChem · 2026Review
- Metabolic mechanisms underlying osmoprotectant-enhanced xylitol biosynthesis from glucose by Zygoascus hellenicus.Bioprocess and biosystems engineering · 2026Article
- Systems-Level Metabolic Regulation Strategies of Xylose Metabolism in Saccharomyces cerevisiae.Biotechnology journal · 2026Review
- Biotechnological applications of D-xylose-fermenting autochthonous yeasts in lignocellulosic biorefineries.Biotechnology for biofuels and bioproducts · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Xylitol, a five-carbon sugar alcohol, is recognized as a desirable sugar alternative due to its low-calorie content and metabolism independent of insulin. Its commercial production generally involves the chemical hydrogenation of D-xylose, an approach that is energy-demanding and environmentally unfriendly. Although fermentation offers a biological alternative, it often suffers from low conversion efficiency and limited yields. However, xylitol is an intermediate metabolite in various microbial species, and its biosynthesis can be enhanced through metabolic engineering. Genetically modifying microbial cell factories-such as bacteria, fungi, and yeast-has shown significant improvements in xylitol production. Furthermore, the precursor xylose, which is utilized by microbes, can be derived from lignocellulosic biomass through hydrolysis, offering a more sustainable and cost-effective production route. This review discusses recent advances in the bioproduction of xylitol and highlights various metabolic engineering strategies employed to enhance xylitol yield in microbial cell factories.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.